Pegaptanib sodium

哌加他尼钠

Report date: 2025/09/12 11:25:03
NME

Base Information

Drug NamePegaptanib sodium
Drug Alias Namepegaptanib培加尼布培加他尼Pegaptanib octasodiumpegaptanibum +[11] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide aptamer
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaDiabetes MellitusRetinal Vein Occlusion +[10] 
Global Approved IndicationsWet age-related macular degenerationMacular Degeneration
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2004/09/17
Country/TerritoryUnited StatesSwedenGermany +[8] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGreater Houston Retina Research Foundation IncPfizer IncJohns Hopkins University +[7] 
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedemaDiabetes MellitusRetinal Vein Occlusion +[10] 

Other Information

ATC CodeS01LA03
Related LinksWikipediaDrugBankKEGG